Janssen To Market Biweekly Risperdal In Japan
This article was originally published in PharmAsia News
Executive Summary
Japan's Janssen Pharmaceutical plans to begin marketing in Japan a new injectable version of Risperdal (risperidone) for treating schizophrena by the end of June. The Johnson & Johnson subsidiary is counting on a biweekly injectable form of the drug to be more attractive to Japanese patients than a daily oral medicine now available. With the new version, Janssen also hopes to make a generic version of the daily drug less attractive. The biweekly version is to be marketed in Japan as Risperdal Consta. (Click here for more - a subscription may be required